

WEDNESDAY, 16th OCTOBER 2019 COMMENCING 10:30 AM
AT THE [COPTHORNE HOTEL CARDIFF](#), COPTHORNE WAY,
CULVERHOUSE CROSS, CARDIFF CF5 6DH

AGENDA

Enclosure

1. **Welcome and introduction**
2. **Apologies**
3. **Declarations of interest**
4. **Minutes of previous meeting** 1/AWMSG/1019
5. **Chairman's report (verbal update)**
6. **Appraisal 1: Limited Submission**
Zanamivir (Dectova®) for the treatment of complicated and potentially life-threatening influenza A or B virus infection in adult and paediatric patients (aged ≥6 months) when:
The patient's influenza virus is known or suspected to be resistant to anti-influenza medicinal products other than zanamivir, and/or other anti-viral medicinal products for treatment of influenza, including inhaled zanamivir, are not suitable for the individual patient. Dectova should be used in accordance with official guidance 2/AWMSG/1019
Appendices
7. **Appraisal 2: Limited Submission**
Glecaprevir/pibrentasvir (Maviret®) for the treatment of chronic hepatitis C virus infection in adolescents aged 12 to < 18 years 3/AWMSG/1019
Appendices
8. **Endocrine management of gender dysphoria in adults: prescribing guidance for non-specialist practitioners** 4/AWMSG/1019
9. **Medicine Identified as a Low Priority for Funding in NHS Wales – Paper 1 (Update to section on liothyronine)** 5/AWMSG/1019
10. **NICE in Wales – Dr Julie Vile, Implementation Facilitator, NICE Field Team (Wales)**

Date of next meeting – Wednesday, 13th November 2019 in Cardiff